The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score -7.67 — distress zone — historically elevated failure riskWatch
- Earnings-manipulation signal · Beneish M -2.90 — no flag raisedOK
- Earnings quality 82/100 — accruals in line with cashOK
Where the revenue comes from
Fiscal 2025, as REGENXBIO Inc. reports it. History and quarterly detail are in the app.
- License And Service$156.3M
- Zolgensma And Itvisma Royalties$83.2M
- Zolgensma Royalties$82.5M
- Nippon Shinyaku Licenses$72.9M
- License And Royalty Revenue$72.9M
Leadership changes
From REGENXBIO Inc.'s own filings, the day they're filed.
- Mitchell Chan · President · appointmenteff. 2024-09-16
- Vittal Vasista · Chief Financial Officer · departureeff. 2024-09-16
- Curran M. Simpson · President · appointmenteff. 2024-07-01
Latest filings
- 8-K · Company announcement2026-06-03
- 10-Q · Quarterly report2026-05-14
- 8-K · Company announcement2026-05-14
- DEF 14A · Annual proxy (pay & governance)2026-04-14
- 8-K · Company announcement2026-03-20
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, every figure source-linked🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask anything about REGENXBIO Inc., every answer cited🔒
- The Intelligence Brief — added when REGENXBIO Inc.'s brief passes our SEC-figure check🔒
Every figure links to the filing it came from, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.